Oncogenic fusions induce an extensive cancer-restricted cryptic proteome in Ewing sarcoma
Proteomic, immunopeptidomic, and immunofluorescence analyses validate neoproteins as tumor-restricted antigens, revealing a therapeutically actionable cancer dark proteome controlled by one oncogenic fusion.